Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255671 · ClinicalTrials.gov registry record
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
A clinical trial of Metastatic Cancer and Brain and Central Nervous System Tumors, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 76
- Enrollment target
- 1
- Study location
NCT00255671 is a study of Metastatic Cancer and Brain and Central Nervous System Tumors that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 76 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00255671, a study of Metastatic Cancer and Brain and Central Nervous System Tumors, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably. PURPOSE: This clinical trial is studying the acute side effects in patients who are undergoing stereotactic radiosurgery for brain tumors or other brain disorders.
Conditions Studied
Interventions
- OTHER Questionnaire
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2005-05 |
| Est. Completion | 2012-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255671
The ClinicalTrials.gov registry entry for NCT00255671 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Questionnaire is the first listed.
NCT00255671 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00255671 about?
NCT00255671 is a clinical study titled "Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders". RATIONALE: Learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably. PURPOSE: This clinical trial is studying the acute side effects in patients who are undergoing ster...
What is the current status of trial NCT00255671?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2005-05. Estimated completion is 2012-05.
What conditions does trial NCT00255671 study?
This clinical trial studies the following conditions: Metastatic Cancer, Brain and Central Nervous System Tumors, Radiation Toxicity.
What interventions are being tested in trial NCT00255671?
The interventions under investigation include: Questionnaire (OTHER).
Who is sponsoring clinical trial NCT00255671?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00255671 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.